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For the current northern hemisphere season, several reports have indicated intense influenza activity [1] [2] [3] [4] [5] . We analysed virological surveillance data from 20 European countries to study the genetic and antigenic characteristics of the circulating influenza viruses and compare them with the vaccine viruses and previously circulating strains.
Virological influenza surveillance in Europe, influenza season 2015/16
Virological influenza surveillance data in the World Health Organization (WHO) European Region are collected on a weekly basis and reported to The European Surveillance System (TESSy), a database hosted by the European Centre for Disease Prevention and Control (ECDC), as previously described [6] . From week 40/2015 to week 4/2016, 49 Member States of the Region reported influenza virus detections to TESSy, including 20 Member States (Belgium, Croatia, Czech Republic, Denmark, Finland, Germany, Greece, Ireland, Latvia, Netherlands, Norway, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, and the United Kingdom (UK)) that also reported antigenic or genetic characterisation data.
The antigenic and genetic reporting categories for TESSy are predefined by the WHO Collaborating Centre for Reference and Research on Influenza, London, for each influenza season. For antigenic characterisation, to denote a virus isolate as being like a vaccine or reference virus its haemagglutination inhibition (HI) titre with post-infection ferret antiserum raised against the reference virus should differ by no more than fourfold. For genetic characterisation, the allocation to reporting category is based on the phylogenetic and amino acid sequence analyses of haemagglutinin (HA) gene.
The summary analysis of the data are presented weekly in the Joint ECDC-WHO Regional Office for Europe weekly 'Flu News Europe' (http://flunewseurope.org/). Data on detections, antigenic and genetic characterisations were extracted on 8 February 2016 for analysis.
Between week 40/2015 and week 4/2016, influenza viruses were detected in 1,879 (19%) of 9,882 sentinel specimens tested in the 20 countries also reporting on virus characterisation. Of these 1,879 specimens, 1,512 (80%) were positive for type A influenza virus and 367 (20%) for type B. Of 1,441 subtyped influenza A viruses, 1,268 (88%) were A(H1N1)pdm09. Of 129 type B viruses with known lineage, 115 (89%) were of the B/ Victoria/2/1987 lineage. Some sequences obtained in this study were not used to construct the phylogenetic tree because they were identical and redundant. The sequences used for the phylogenetic analysis were moreover only those of suitable length, and encode HA1 amino acids 3-327. These included sequences reported by the Czech Republic, Finland, Greece, Netherlands, Norway, Portugal, Romania, Russia, Slovenia, Spain and Sweden as well as sequences from reference A(H1N1)pdm09 viruses. The tree was constructed with the neighbour-joining method, using Kimura-2 parameter-corrected distances and bootstrapped with 1,000 replicates, Molecular Evolutionary Genetics Analysis (MEGA) software version 5.0. Analysis of A(H1N1)pdm09 HA gene sequences from 12 countries (Czech Republic, Finland, Greece, Ireland, Netherlands, Norway, Portugal, Romania, Russia, Slovenia, Spain and Sweden) reported to TESSy, with provision of accession numbers in publicly accessible databases, confirmed that all these analysed viruses possessed the signature amino acid variations that define subgroup 6B viruses: D97N, K163Q, S185T, K283E and A256T [7] [8] [9] . All 215 analysed sequences, apart from two viruses isolated in Russia, also carried P83S and I321V substitutions in HA1.
Virus characterisation
The majority of sequences (173 of 215 TESSy-reported viruses) also possessed the amino acid signature of subclade 6B.1 and formed a separate branch in the phylogenetic analysis ( Figure 1, Figure 2 ). The 6B.1 subclade is characterised by the amino acid substitutions S84N (present in a wider subgroup), S162N and I216T [8] . Six viruses carried amino acid substitutions V152T, V173I, D501E (the latter in HA2) characterising 6B.2 subclade. In addition the five most recently sampled of these six 6B.2 viruses all possessed the R113K, D127E and E374Q substitutions ( Figure 1 ).
The highest number of accumulated variations in the known antigenic sites were observed in the antigenic site Ca. All subgroup 6B viruses possessed the K163Q substitution, while the vast majority (173/215; 80%) also possessed the S162N substitution in HA1, resulting in a gain of a potential glycosylation site. Additional Amino acid not previously associated with a specific feature is marked in grey. Amino acid that creates a new potential N-glycosylation site is marked in magenta.
variations observed were S162K, D168N, K170E, R205K, A215G, E235D and a partial A139D. Cb antigenic site variation A73S was observed in four viruses from Spain, one of which also possessed substitution N156K in Sa antigenic site. Another Norwegian virus had a N156S substitution in Sa antigenic site. Notably, all 6B.2 viruses and also two of the 6B viruses not belonging to any of the newly identified subgroups possessed substitutions affecting the loop that consists of amino acid positions 151 to 159 located adjacent to the receptor binding site. 
Discussion
Continuous surveillance of influenza viruses is essential for detecting emerging new variant strains and providing viruses for vaccine production [10] . In Europe, within the detected A subtypes, influenza A(H1N1) pdm09 predominated during 2010/11, 2012/13 and 2013/14 seasons and concerned 97% [11] , 62% [12] and 53% [13] of subtyped influenza viruses respectively, with variation in country-specific proportions. The A(H1N1)pdm09 vaccine component A/California/7/2009 has not been changed since the 2009 pandemic and the circulating A(H1N1)pdm09 viruses have remained antigenically similar to the virus included in the vaccines throughout the influenza 2009/10 to 2015/16 seasons. However, since 2013, several reports have indicated the emergence of an expanding subgroup of A(H1N1)pdm09 viruses, designated 6B [1, 8, 9] . This subgroup appeared in 2012/13 and became predominant in 2013/14 [14] .
In this study, we observe the further emergence of a subclade within the 6B subgroup, designated 6B.1 [15] , which accounted for the majority of the A(H1N1)pdm09 viruses detected across the WHO European Region during the first weeks of the 2015/16 influenza season. In addition, the surveillance data show a change in the predominant B virus lineage from B/Yamagata which predominated in the preceding three seasons in Europe to B/Victoria.
Our data are preliminary for this season and are based on influenza surveillance without detailed reporting of clinical symptoms or vaccination status. Our genetic analysis was only based on the HA gene and does not extend to changes e.g. in genes encoding internal proteins of influenza viruses. The data reported to TESSy do not include antigenic titres and therefore no direct analysis of antigenic properties was possible. However, the antigenic reports rely on national influenza centres' antigenic analysis that the viruses reported as like to vaccine virus were not more than fourfold different in HI titres from the vaccine or reference viruses. The viruses which were genetically characterised are not necessarily the same than the viruses that were antigenically characterised. a Genetic and antigenic groups used for reporting into The European Surveillance System are defined by World Health Organization Collaborating Centre for Reference and Research on Influenza for each influenza season. For antigenic characterisation, to denote a virus isolate as being like a vaccine or reference virus its haemagglutination inhibition (HI) titre with post-infection ferret antiserum raised against the reference virus should differ by no more than fourfold. For genetic characterisation, the allocation to reporting category is based on the phylogenetic and amino acid sequence analyses of haemagglutinin (HA) gene. b These genetic groups contain viruses with antigenic properties similar to the viruses included in the trivalent influenza vaccine for 2015/16. c These genetic groups contain viruses with antigenic properties dissimilar to the viruses included in the trivalent influenza vaccine for 2015/16. d Viruses in this genetic group have antigenic properties similar to those of the vaccine component (B/Brisbane/60/2008) recommended for use in quadrivalent influenza vaccines for 2015/16. 
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Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)'s EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study [15] .
The emergence of a new A(H1N1)pdm09 subclade may eventually affect the susceptibility of the population to the currently circulating A(H1N1)pdm09 viruses, e.g. by viruses drifting closer to become immune escape variants. It is not clear whether the emergence and predominance of subclade 6B.1 has been driven by immune selection or what its impact on vaccine effectiveness may be and this needs assessment e.g. by generating lineage-specific estimation of vaccine effectiveness. Early vaccine effectiveness estimates for A(H1N1) pdm09 this season compared with the previous ones are not significantly different [16] from previous seasons. As to the severity observed this season [1] [2] [3] [4] , similar observations have been made also in earlier seasons e.g. in 2010/11 in the United Kingdom, which experienced notably severe A(H1N1)pdm09 impact in the first post-pandemic season.
Notably, recent studies have demonstrated that antigenic change in A(H1N1)pdm09 viruses is mainly caused by single amino acid substitutions affecting the loop located adjacent to the receptor binding site [17] ; eight of the 215 analysed 2015/16 viruses possessed such substitutions, all six of the viruses in subclade 6B.2 and two in 6B subgroup, that do not belong to any of the newly emerged subclades.
Further enhancement of the antigenicity and virulence of influenza virus has been attributed to shielding of the major antigenic epitopes by alteration of N-linked glycosylation sites [18] . D127E substitution seen in 6B.2 has been associated with antigenic change of other influenza viruses through modelling [17] . The change at position 173 (V173I) also in the 6B.2 subclade of viruses is located in antigenic site Ca1 (position 169-173), and therefore a change here could contribute to antigen drift. It has been proposed that the evolution of A(H1N1)pdm09 will involve the acquisition of additional glycosylations, as for former seasonal A(H1N1) HA [19] . Noteworthy, 80% of the analysed HA sequences have gained a potential glycosylation site S162N. No D222G/E/N substitutions were detected, nor N129D which was recently identified in India in two severe or fatal cases [9] . If the emerging groups continue to diversify from the vaccine component, their antigenic properties may change and the vaccine effectiveness might be reduced. WHO recommended not to change the vaccine component of A(H1N1)pdm09 for the northern hemisphere 2016/17 season [20] .
Early vaccine effectiveness estimates for 2015/16 are not yet available for A(H3N2) and B viruses which have been detected in lower numbers in most countries. The B/Victoria virus component is available only in the quadrivalent vaccines in the northern hemisphere for this season. As the majority of the countries use trivalent vaccines, the lineage switch from B/Yamagata to B/Victoria may contribute to lower vaccine effectiveness against influenza B. For A(H3N2), the current component of influenza vaccines is expected to have improved vaccine effectiveness compared with the two previous seasons [21, 22] . In the southern hemisphere, seasonal influenza vaccine has been demonstrated to have an overall effectiveness against A(H3N2) of 36% (95% confidence interval (CI): 11-54)) for general practice encounters and 50% (95%-CI: 20-68) for hospitalisations in 2015 [23] . Despite the changes in the genetic makeup of influenza A(H1N1)pdm09 viruses and the predominance of B/Victoria lineage over B/Yamagata lineage, seasonal influenza vaccine remains the single most effective measure to prevent severe outcomes of influenza.
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